Pharma stocks prove to be a defensive and resilient investment option for investors due to its constant market demand, high profitability, growth potential and diversification benefits. These stocks are unaffected by economic fluctuations and offer consistent dividends to investors.
Here are four such defensive pharma stocks to buy with an upside potential of up to 22 percent:
Zydus LifeSciences Limited
Zydus Lifesciences operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
K R Choksey, a leading wealth management brokerage has set a target price of Rs.1,439 per share on Zydus Lifesciences Limited, with an upside potential of 22 percent.
With a market capitalization of Rs.1.19 lakh crore, the share price of the company is currently trading at Rs.1,178 per share, down by 2.62 percent from its previous closing price.
Also Read
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals is a global research-led pharmaceutical company engaged in generics, specialty, and over-the-counter (OTC) businesses. The company operates in over 80 countries.
K R Choksey, a leading wealth management brokerage has set a target price of Rs.1,894 per share on Glenmark Pharmaceuticals Limited, with an upside potential of 13 percent.
With a market capitalization of Rs.47,556 crore, the share price of the company is currently trading at Rs.1,681.5 per share, rising 0.3 percent from its previous closing price.
Ipca Laboratories Limited
Ipca Laboratories is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 active pharmaceutical ingredients (APIs) across various therapeutic segments.
Sharekhan, a full-service stock broker, has set a target price of Rs.1,600 per share on Ipca Laboratories Limited, with an upside potential of 15 percent.
With a market capitalization of Rs.35,290 crore, the share price of the company is currently trading at Rs.1,390.65 per share, falling 0.87 percent from its previous closing price.
Granules India Limited
Granules India Limited is a multinational pharmaceutical company specialising in the production of off-patent drugs and operates in the contract research and manufacturing (CRAM) sector.
K R Choksey, a renowned wealth management broker has set a target price of Rs.769 per share on Granules India Limited, with an upside potential of 13 percent.
With a market capitalization of Rs.16,602 crore, the share price of the company is currently trading at Rs.683.65 per share, falling 0.16 percent from its previous closing price.
Written by – Siddesh S Raskar
Also Read
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
